TickerTalks
Browse all tickers →
TickerTalks›$PFE
PFPFE

Pfizer Inc.

Strong FundamentalsStrong FundamentalsRevenue growing 5% YoY at strong margins3 insiders bought $3.0M in 30 daysConsistent chatter on X (657/wk), no spike
$PFE·$143B·Drug Manufacturers - General·Healthcare
$28.46+1.8%YTD+1.7%1Y+13.9%
Mentions · last 7 days
2026-08-22: 27 posts2026-08-23: 33 posts657-0%
Price updated 8h ago·X counts updated 8d ago
PFPFE
$PFEPfizer Inc.
$28.46+1.79%657 posts-0%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $PFE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Proven numbersWinding up for a moveAI verdict · as of 2026-09-01

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

The big-pharma dividend name where directors just wrote $3M of open-market buys — the patent cliff is real, but so is the cash flow.

Pfizer is a global biopharma with a broad cardiovascular, oncology, and vaccines franchise — a mature earnings-and-dividend name that has spent two years working off the COVID revenue collapse. The setup coiled into September on a trio of director buys and a fresh COVID vaccine approval.

  • Fundamentals are stable, not exciting: TTM revenue growth is low-single-digits, operating margin 23%, FCF yield 6.4%, and PE 20x — the business generates real cash and pays it out (~6% dividend).
  • Insider signal is genuinely bullish: CEO Bourla bought $1M at $26.34, board members Buckley and Blaylock bought ~$1M each at $25-26 — three open-market director/officer purchases inside two weeks is a rare cluster and lands as real conviction.
  • Position sits at the 94th percentile of the 52-week range on volume running 17% above normal — the tape is being accumulated into the coiled setup, and four straight EPS beats build the base for a re-rate.
  • The overhangs are real: the 2033 patent cliff, the Trump drug-pricing deal being announced, and lingering questions on the Vesper 3 obesity trial after past oral GLP-1 discontinuations — none dispositive, but each caps upside until resolved.

The forward look depends on the Trump drug-pricing announcement landing without draconian terms, plus the Nov 3 Q3 print delivering another beat with the CFO addressing the patent-cliff plan. A punitive pricing deal breaks the setup; a mild outcome plus a pipeline milestone continues the coil.

Agrees with X sentimentHalf-agreement lands closest to reality: the yield-hunter case (6% dividend, 9x adjusted multiple, falling debt, XFG vaccine approval) is validated by the mechanics and by three director open-market buys; the skeptics' 2033 patent cliff and Vesper 3 concerns are real medium-term overhangs but haven't broken the accumulation pattern yet.

What to watch: The Trump drug-pricing announcement terms (near-term), and the Nov 3 Q3 print for CFO commentary on the 2033 patent-cliff replacement pipeline. A punitive pricing deal or Vesper 3 disappointment would invalidate the setup; a mild pricing outcome plus a pipeline milestone continues the coil.

On the calendar: 2026-11-03 — Q3 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Mixed sentiment28 posts analyzed · as of 2026-08-30

The conversation on Pfizer is split between yield hunters and pipeline skeptics. Bulls cite the fresh FDA approval of the XFG-adapted COVID vaccine with BioNTech, a 6% dividend, falling debt, and a 9x multiple; skeptics dwell on the 2033 patent cliff, questions around the Vesper 3 obesity trial, and past discontinuations of oral GLP-1 programs. Unusual puts and Morgan Stanley notes on adjacent immunology add technical noise.

Read the AI verdict + X sentiment for $PFE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Makes vaccines, oncology drugs, and small-molecule medicines while rebuilding revenue after COVID product declines.

Industry overviewAI analysisGenerated by AI from underlying data

Where Drug Manufacturers - General sits in its cycle right now — and what that implies for $PFE.

Drug Manufacturers - General · Healthcare

GLP-1 obesity/diabetes franchise expansion is the sector's defining growth dynamic; LLY and NVO are capturing most of the incremental spend while the industry realigns R&D pipelines. Patent cliff management — biosimilar exposure and pipeline offset — is the critical risk for legacy pharma names.

What this means for $PFE

Partial — upstream oil & gas exposure ties to commodity price cycle; Pfizer Inc.

Top industry ETF

$IHEiShares U.S. Pharmaceuticals ETF
+19.1%YTD
+45.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
19.8How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
8.0%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
23.4%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
6.4%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
2.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
8.4%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
69.3%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.7Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q2 2026Aug 4, 2026$0.77$0.68+12.9%
Q1 2026May 5, 2026$0.75$0.72+3.9%
Q4 2025Feb 3, 2026$0.66$0.57+16.4%
Q3 2025Nov 4, 2025$0.87$0.63+37.4%
Next earningsTue, Nov 3·consensus EPS $0.79

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$14.5B+5.4%67.3%27.9%$0.47$2.2B
Q4 FY25$17.6B-1.2%70.0%21.0%$-0.29$4.5B
Q3 FY25$16.7B-5.9%74.9%21.3%$0.62$4.0B
Q2 FY25$14.7B+10.3%64.3%24.4%$0.51$-1.2B

Forward consensus

5-year forecast · up to 21 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$61.8B$60.7B – $62.6B$2.94$2.84 – $3.0318
FY27$59.3B$57.2B – $60.8B$2.84$2.61 – $3.0018
FY28$54.7B$51.7B – $58.4B$2.44$1.58 – $2.7821
FY29$53.4B$51.2B – $55.5B$2.30$2.18 – $2.4210
FY30$53.8B$51.6B – $55.9B$2.35$2.22 – $2.4710

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.1.2×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.94%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+11.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+9.0%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMega float · 5.7B shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.8% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Cluster buy3 insiders bought shares in the last 30 days.

Recent transactions

BuyAug 12Albert BourlaCEO38.0K sh$1.0MSellAug 5Jennifer B. DamicoSVP & Controller3.3K sh$83KBuyAug 5Mortimer J BuckleyDirector37.6K sh$960KBuyAug 5Ronald E BlaylockDirector39.2K sh$999KSellJun 9Jennifer B. DamicoSVP & Controller2.0K sh$51K
+ 36 other (36 awards) in window

See when $PFE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

3New insider — initial holdingsAug 283
AI summary

Cecile Guegan, Executive Vice President of Pfizer Inc., filed a Form 3 on August 28, 2026, reporting beneficial ownership of 149,505 shares of common stock plus stock appreciation rights (SARs) on approximately 104,129 underlying shares across multiple grants at strike prices ranging from $25.75 to $45.96, exercisable between 2027–2031. Routine insider ownership disclosure following a change in reporting status. No market significance.

8-KPress release / Reg FDJun 188-K — Item 7.01: Press release / Reg FD
AI summary

Pfizer reaffirmed its full-year 2026 financial guidance on June 18, 2026, concurrent with the CFO departure announcement. Guidance is unchanged: revenues of $59.5–$62.5 billion and Adjusted Diluted EPS of $2.80–$3.00, consistent with the December 2025 introduction and May 5, 2026 Q1 call reaffirmation. The same-day guidance reaffirmation alongside the CFO transition is designed to signal management confidence in the financial outlook and contains investor concern from the leadership change. Stable outlook — Pfizer is holding guidance range despite a CFO departure mid-year.

8-KOfficer or director changeJun 188-K — Item 5.02: Officer or director change
AI summary

Pfizer CFO Dave Denton notified the company on June 16, 2026 that he will resign effective August 15, 2026 to pursue a role in consumer goods outside pharmaceuticals, with no disagreement over Pfizer's financial or operating results. Cecile Guegan (55), SVP Finance, Global Biopharmaceutical Business (Pfizer since 2005, current role since 2022), will serve as Interim CFO from August 16, 2026 while a comprehensive permanent search is conducted. A CFO departure mid-year is material for a large-cap pharma navigating post-COVID product portfolio transitions; the same-day guidance reaffirmation (see companion 8-K) was filed simultaneously to offset investor concern.

3/ANew insider — initial holdingsApr 273/A
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3/A (amended) for PFE on 2026-04-27, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

8-KShareholder voteApr 278-K — Item 5.07: Shareholder vote
AI summary

PFE held its Annual Meeting of stockholders around 2026-04-27 (8-K Item 5.07). Stockholders elected 11 directors to the board. Independent auditor ratification was approved. Routine governance event — monitor for unusually high withhold votes as an activist signal.

3New insider — initial holdingsApr 103
AI summary

Form filed by More than One Reporting Person Table I - Non-De filed a Form 3 (initial ownership statement) for PFE on 2026-04-10, initiating required Section 16 reporting. Role: of Reporting Person. Form 3 is a mandatory administrative filing upon first becoming an insider or 10%+ holder; it does not reflect a purchase or sale event.

+ 16 other (3 13Gs · 2 13Fs · 2 10-Qs · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakerscnbc.com·15h agoFrom Padcev to PF-08634404: Pfizer's Oncology Growth Pushzacks.com·16h agoPfizer and Starbucks: One Turnaround Is Built to Last, and One Isn't247wallst.com·19h agoTake Two Interactive, Nvidia, Cheniere Energy And A Health Care Stock: CNBC's ‘Final Trades'benzinga.com·21h agoArcher Investment Corp Acquires Shares of 73,546 Pfizer Inc. $PFEdefenseworld.net·3d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Drug Manufacturers - General

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$MRK$LLY$NVO$JNJ$GILD$ABBV$AMGN$AZN
Voices on X · top 15 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport